logo BDSP

Base documentaire

  1. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in germany.

    Article - En anglais

    Acellular pertussis vaccines are less reactogenic than whole cell pertussis vaccines, but they are also more expensive.

    Based on simulation models, we compared the costs and effects of three alternative pertussis vaccination strategies in German children to « no prevention » : (1) vaccination with whole-cell vaccine at 45% coverage (vaccine efficacy 90%), (2) vaccination with acellular vaccine at 45% coverage (vaccine efficacy 85%), and (3) vaccination with acellular vaccine at 90% coverage.

    In the two low coverage scenarios expected annual savings in direct medical costs through prevention of disease were larger for whole-cell than for acellular vaccination (252 vs 216 million DM, respectively).

    Direct costs for treating the more important adverse events induced by whole-cell vaccination (16.9 million DM annually) did not outweigh the higher direct costs of pertussis infections not prevented with the acellular vaccine and the higher price of the acellular vaccine.

    However, vaccination with acellular pertussis vaccine rapidly becomes as cost saving as vaccination with whole-cell vaccine as soon as vaccination coverage can be raised from 45% to 52.5% with acellular vaccine.

    Acellular vaccination is also the superior alternative when considering indirect cost savings resulting from reduction in work-loss due to adverse events.

    Mots-clés Pascal : Coqueluche, Bactériose, Infection, Epidémiologie, Arbre décision, Bordetella pertussis, Bactérie, Vaccination, Analyse coût efficacité, Vaccin acellulaire, Etude comparative, Modèle simulation, Enfant, Homme, Allemagne, Europe, Evaluation, Appareil respiratoire pathologie, Immunoprophylaxie, Economie santé

    Mots-clés Pascal anglais : Whooping cough, Bacteriosis, Infection, Epidemiology, Decision tree, Bordetella pertussis, Bacteria, Vaccination, Cost efficiency analysis, Acellular vaccine, Comparative study, Simulation model, Child, Human, Germany, Europe, Evaluation, Respiratory disease, Immunoprophylaxis, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0248527

    Code Inist : 002B05A02. Création : 11/09/1998.